DNA / GINKGO ALERT: Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc. on Behalf of Ginkgo Stockholders and Encourages Investors to Contact the Firm

Ginkgo Bioworks is analyzed based on Porter's Five Forces framework for competitive dynamics. The threat of competition in Ginkgo's R&D discovery busi more_horizontal

Famous investor Cathie Wood has been buying up shares of Ginkgo Bioworks over the past year. The company's revenue has climbed in recent years, but th more_horizontal

Ginkgo Bioworks' stock price has been volatile due to mixed Q2 earnings, partnership announcements, and concerns about the macro environment. Antheia more_horizontal

While the S&P 500 remains up on the year, the biotech sector is down. Even though the broader market is showing signs of strength in areas like AI and more_horizontal

Although the innovation space may be on the verge of a broader correction, certain ideas may pop higher, which brings us to Cathie Wood stocks to make more_horizontal

Growth stocks are an important element of a well-balanced portfolio. Ginkgo Bioworks and Harmony Biosciences are two risky growth plays that could del more_horizontal

Shockwave Medical just got a boost from a Medicare decision on one of its products. Bio-Techne is benefiting from increased cell and gene therapy reve more_horizontal

Ginkgo Bioworks and Pfizer announced a new RNA therapeutics collaboration today. In response, Ginkgo Bioworks' stock jumped by double digits in early- more_horizontal